ARIAD Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer by regulating cell signaling with small molecules in the United States. Its lead cancer product candidate, AP23573, is an mTOR inhibitor for the treatment of solid tumors, including sarcomas, hormone refractory prostate cancer, and endometrial cancer. AP23573 is in multiple Phase II and Ib clinical trials as a single agent in patients with hematologic malignancies and solid tumors. The company also develops small-molecule drugs that regulate cell signaling, as well as holds licenses for NF-kB cell-signaling technology, which could be used for the treatment of disorders, such as...